drugset
Drugs / peripheral blood lymphocyte therapy
last change May 2018 re-read 2 minutes ago

peripheral blood lymphocyte therapy

also known as aDLI · alloanergized donor lymphocyte infusion

Cell therapy

Developed for
leukemia · myelodysplastic syndrome
Investigated by
Dana-Farber Cancer Institute · National Cancer Institute (NCI) · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

today NCT00376480 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00376480 Jun 2005 → Jun 2010 leukemia, myelodysplastic syndrome Dana-Farber Cancer Institute Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as peripheral blood lymphocyte therapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT00376480 ↗
Known as aDLI “alloanergized donor lymphocyte infusion (aDLI)” PMID 29769208 ↗ May 2018
Known as alloanergized donor lymphocyte infusion “alloanergized donor lymphocyte infusion (aDLI)” PMID 29769208 ↗ May 2018
Modality Cell therapy “ex vivo anergized donor peripheral blood mononuclear cells (PBMC)” NCT00376480 ↗